Abstract
The predominance of insulin resistance, T2D linked pancreatic cancer has increased throughout the world. The insulin/IGF signaling pathway related to insulin resistance, T2D and pancreatic cancer has been described. In this context, we have demonstrated the role of miRNAs in cancer progression and control of miRNAs in insulin/IGF signaling pathway, and pancreatic cancer. In this paper, an overview was depicted about the role of following miRNAs in pancreatic development and insulin secretion (miR-375, miR-7, miR-124a2, miR-195, miR-126, miR-9, miR-96, miR-34a); insulingrowth factor-1 receptor expression (miR-7, miR-139, miR-145, miR-1); the diabetes-associated pancreatic cancer pathway genes such as IRS, PI3K, AKT/PKB (miR-128a, miR-19a, miR-21, miR-29 a/b/c); mTOR protein regulation (miR- 99, miR-21, miR-126, and miR-146a) etc. At last, we have also explained the role of miRNAs in diagnostic marker (miR- 200, miR-21, miR-103, miR-107, and miR-155) and as a therapeutic modulator (miR-34, miR-21, miR-221, and miR-101) in pancreatic cancer.
Keywords: miRNA, insulin/IGF-mTOR signaling pathway, insulin resistance, type-2 diabetes, pancreatic cancer.
Current Drug Targets
Title:miRNAs in Insulin Resistance and Diabetes-Associated Pancreatic Cancer: The ‘Minute and Miracle’ Molecule Moving as a Monitor in the ‘Genomic Galaxy’
Volume: 14 Issue: 10
Author(s): Chiranjib Chakraborty, George Priya Doss. C and Sanghamitra Bandyopadhyay
Affiliation:
Keywords: miRNA, insulin/IGF-mTOR signaling pathway, insulin resistance, type-2 diabetes, pancreatic cancer.
Abstract: The predominance of insulin resistance, T2D linked pancreatic cancer has increased throughout the world. The insulin/IGF signaling pathway related to insulin resistance, T2D and pancreatic cancer has been described. In this context, we have demonstrated the role of miRNAs in cancer progression and control of miRNAs in insulin/IGF signaling pathway, and pancreatic cancer. In this paper, an overview was depicted about the role of following miRNAs in pancreatic development and insulin secretion (miR-375, miR-7, miR-124a2, miR-195, miR-126, miR-9, miR-96, miR-34a); insulingrowth factor-1 receptor expression (miR-7, miR-139, miR-145, miR-1); the diabetes-associated pancreatic cancer pathway genes such as IRS, PI3K, AKT/PKB (miR-128a, miR-19a, miR-21, miR-29 a/b/c); mTOR protein regulation (miR- 99, miR-21, miR-126, and miR-146a) etc. At last, we have also explained the role of miRNAs in diagnostic marker (miR- 200, miR-21, miR-103, miR-107, and miR-155) and as a therapeutic modulator (miR-34, miR-21, miR-221, and miR-101) in pancreatic cancer.
Export Options
About this article
Cite this article as:
Chakraborty Chiranjib, Doss. C Priya George and Bandyopadhyay Sanghamitra, miRNAs in Insulin Resistance and Diabetes-Associated Pancreatic Cancer: The ‘Minute and Miracle’ Molecule Moving as a Monitor in the ‘Genomic Galaxy’, Current Drug Targets 2013; 14 (10) . https://dx.doi.org/10.2174/13894501113149990182
DOI https://dx.doi.org/10.2174/13894501113149990182 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Lapatinib as a Chemotherapeutic Drug
Recent Patents on Anti-Cancer Drug Discovery AMPK as a Potential Anticancer Target - Friend or Foe?
Current Pharmaceutical Design Insight into p95HER2 in Breast Cancer: Molecular Mechanisms and Targeted Therapies
Recent Patents on DNA & Gene Sequences Hedgehog Signaling and Urological Cancers
Current Drug Targets Possible Role of NUCB2/nesfatin-1 in Adipogenesis
Current Pharmaceutical Design Non-coding RNAs in Exosomes: New Players in Cancer Biology
Current Genomics Combination of Anti-EGFR Drugs and Other Molecular Targeted Agents as Anti-Cancer Strategy
Current Cancer Therapy Reviews Image-Guided Drug Delivery with Single-Photon Emission Computed Tomography: A Review of Literature
Current Drug Targets Breaking the DNA Damage Response via Serine/Threonine Kinase Inhibitors to Improve Cancer Treatment
Current Medicinal Chemistry Reprograming Carcinoma Associated Fibroblasts by microRNAs
Current Molecular Medicine Deciphering the Role of Forkhead Transcription Factors in Cancer Therapy
Current Drug Targets Metabolic Homeostasis and Colonic Health: the Critical Role of Short Chain Fatty Acids
Current Nutrition & Food Science MMP Inhibitors in Cardiac Diseases: An Update
Recent Patents on Cardiovascular Drug Discovery Long Non-Coding RNAs As Epigenetic Regulators in Cancer
Current Pharmaceutical Design Genetics of Obesity: What have we Learned?
Current Genomics Recent Advancements in Nanotechnology for Oral Cancer: a Review
Current Drug Therapy Near-Infrared Quantum Dot Contrast Agents for Fluorescence Tissue Imaging: A Phantom Study
Current Nanoscience Plant-based Natural Products for Wound Healing: A Critical Review
Current Drug Research Reviews In-vitro Antioxidant activity of ‘Aswathy Chooranam’- a Siddha Drug
Current Traditional Medicine Oxidative Stress Biology and Cell Injury During Type 1 and Type 2 Diabetes Mellitus
Current Neurovascular Research